I will suggest to read protocol of our CD12 study .
It showed it has 2 groups of patients .
Group A - severe ,
Group B - critical
Those are not some subgroups discovered after study was finished .
Those are 2 defined groups , in a protocol approved by the FDA .,
And even with 2 doses showed that Leronlimab, without a question is saving lives at least in group B, critical .
And since so many are dying without one good drug approved for this group of patients .
Group B from CD12 protocol should have EUA or approval with phase 4 at the end of this study ..
No , not the Biogen Alz drug , but Leronlimab should be approved then ..
Many lives will be saved by now ..
History will judge all this ..
Imo